Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment

Raghavendra Gowda, Saketh S. Dinavahi, Soumya Iyer, Shubhadeep Banerjee, Rogerio Neves, Colette R. Pameijer, Gavin Robertson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A2 inhibitor, which can inhibit multiple key pathways responsible for the development of recurrent resistant disease. Free ATK is toxic, limiting its efficacy as a therapeutic agent. Hence, a novel nanoliposomal delivery system called NanoATK was developed, which loads 61.7% of the compound and was stable at 4oC for 12 weeks. The formulation decreased toxicity-enabling administration of higher doses, which was more effective at inhibiting melanoma cell growth compared to free-ATK. Mechanistically, NanoATK decreased cellular proliferation and triggered apoptosis to inhibit melanoma xenograft tumor growth without affecting animal weight. Functionally, it inhibited the cPLA2, AKT, and STAT3 pathways. Our results suggest the successful preclinical development of a unique nanoliposomal formulation containing ATK for the treatment of melanoma.

Original languageEnglish (US)
Pages (from-to)865-875
Number of pages11
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number3
DOIs
StatePublished - Apr 1 2018

Fingerprint

Ketones
Melanoma
Toxicity
Drug Resistance
Nanotechnology
Oncology
Poisons
Cell growth
Cell death
Growth
Drug-Related Side Effects and Adverse Reactions
Drug delivery
Heterografts
Pharmaceutical Preparations
Nanoparticles
Tumors
Neoplasms
Animals
Cell Proliferation
Apoptosis

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

@article{db3eae6b48c04c5e9456583a066f4adc,
title = "Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment",
abstract = "Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A2 inhibitor, which can inhibit multiple key pathways responsible for the development of recurrent resistant disease. Free ATK is toxic, limiting its efficacy as a therapeutic agent. Hence, a novel nanoliposomal delivery system called NanoATK was developed, which loads 61.7{\%} of the compound and was stable at 4oC for 12 weeks. The formulation decreased toxicity-enabling administration of higher doses, which was more effective at inhibiting melanoma cell growth compared to free-ATK. Mechanistically, NanoATK decreased cellular proliferation and triggered apoptosis to inhibit melanoma xenograft tumor growth without affecting animal weight. Functionally, it inhibited the cPLA2, AKT, and STAT3 pathways. Our results suggest the successful preclinical development of a unique nanoliposomal formulation containing ATK for the treatment of melanoma.",
author = "Raghavendra Gowda and Dinavahi, {Saketh S.} and Soumya Iyer and Shubhadeep Banerjee and Rogerio Neves and Pameijer, {Colette R.} and Gavin Robertson",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.nano.2017.12.020",
language = "English (US)",
volume = "14",
pages = "865--875",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "3",

}

Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment. / Gowda, Raghavendra; Dinavahi, Saketh S.; Iyer, Soumya; Banerjee, Shubhadeep; Neves, Rogerio; Pameijer, Colette R.; Robertson, Gavin.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 3, 01.04.2018, p. 865-875.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment

AU - Gowda, Raghavendra

AU - Dinavahi, Saketh S.

AU - Iyer, Soumya

AU - Banerjee, Shubhadeep

AU - Neves, Rogerio

AU - Pameijer, Colette R.

AU - Robertson, Gavin

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A2 inhibitor, which can inhibit multiple key pathways responsible for the development of recurrent resistant disease. Free ATK is toxic, limiting its efficacy as a therapeutic agent. Hence, a novel nanoliposomal delivery system called NanoATK was developed, which loads 61.7% of the compound and was stable at 4oC for 12 weeks. The formulation decreased toxicity-enabling administration of higher doses, which was more effective at inhibiting melanoma cell growth compared to free-ATK. Mechanistically, NanoATK decreased cellular proliferation and triggered apoptosis to inhibit melanoma xenograft tumor growth without affecting animal weight. Functionally, it inhibited the cPLA2, AKT, and STAT3 pathways. Our results suggest the successful preclinical development of a unique nanoliposomal formulation containing ATK for the treatment of melanoma.

AB - Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A2 inhibitor, which can inhibit multiple key pathways responsible for the development of recurrent resistant disease. Free ATK is toxic, limiting its efficacy as a therapeutic agent. Hence, a novel nanoliposomal delivery system called NanoATK was developed, which loads 61.7% of the compound and was stable at 4oC for 12 weeks. The formulation decreased toxicity-enabling administration of higher doses, which was more effective at inhibiting melanoma cell growth compared to free-ATK. Mechanistically, NanoATK decreased cellular proliferation and triggered apoptosis to inhibit melanoma xenograft tumor growth without affecting animal weight. Functionally, it inhibited the cPLA2, AKT, and STAT3 pathways. Our results suggest the successful preclinical development of a unique nanoliposomal formulation containing ATK for the treatment of melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85042030097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042030097&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2017.12.020

DO - 10.1016/j.nano.2017.12.020

M3 - Article

C2 - 29317343

AN - SCOPUS:85042030097

VL - 14

SP - 865

EP - 875

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 3

ER -